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Abstract
The prognosis of epithelial ovarian cancer is poor in part due to the high frequency of chemoresistance. Recent evidence
points to the Toll-like receptor-4 (TLR4), and particularly its adaptor protein MyD88, as one potential mediator of this
resistance. This study aims to provide further evidence that MyD88 positive cancer cells are clinically significant, stem-like
and reproducibly detectable for the purposes of prognostic stratification. Expression of TLR4 and MyD88 was assessed
immunohistochemically in 198 paraffin-embedded ovarian tissues and in an embryonal carcinoma model of cancer
stemness. In parallel, expression of TLR4 and MyD88 mRNA and regulatory microRNAs (miR-21 and miR-146a) was assessed,
as well as in a series of chemosensitive and resistant cancer cells lines. Functional analysis of the pathway was assessed in
chemoresistant SKOV-3 ovarian cancer cells. TLR4 and MyD88 expression can be reproducibly assessed via
immunohistochemistry using a semi-quantitative scoring system. TLR4 expression was present in all ovarian epithelium
(normal and neoplastic), whereas MyD88 was restricted to neoplastic cells, independent of tumour grade and associated
with reduced progression-free and overall survival, in an immunohistological specific subset of serous carcinomas, p,0.05.
MiR-21 and miR-146a expression was significantly increased in MyD88 negative cancers (p,0.05), indicating their
participation in regulation. Significant alterations in MyD88 mRNA expression were observed between chemosensitive and
chemoresistant cells and tissue. Knockdown of TLR4 in SKOV-3 ovarian cells recovered chemosensitivity. Knockdown of
MyD88 alone did not. MyD88 expression was down-regulated in differentiated embryonal carcinoma (NTera2) cells,
supporting the MyD88+ cancer stem cell hypothesis. Our findings demonstrate that expression of MyD88 is associated with
significantly reduced patient survival and altered microRNA levels and suggest an intact/functioning TLR4/MyD88 pathway
is required for acquisition of the chemoresistant phenotype. Ex vivo manipulation of ovarian cancer stem cell (CSC)
differentiation can decrease MyD88 expression, providing a potentially valuable CSC model for ovarian cancer.
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Introduction
Ovarian cancer is one of the most common and lethal cancers in
women [1,2], with incidences and mortality predicted to increase
in western countries [3]. Epithelial ovarian cancers (EOCs)
comprise the vast majority of adult ovarian malignancies, which
are most commonly serous carcinomas [4,5]. As ovarian cancer is
often asymptomatic in its early stages or presents with vague
symptoms mimicking extra-ovarian disease; most patients (70–
75%) present with widespread disease at diagnosis with a resulting
high mortality rate [6]. Current treatment options include surgery
and platinum and/or taxane-based chemotherapy [7]. Although
EOC typically responds very well to standard chemotherapy, with
initial 70–80% response rates, this is frequently followed by
recurrence that is often chemoresistant [8,9]. Predicting and
overcoming this chemoresistance remains a key challenge in
treatment, however there are currently no available biomarkers
(serum or tissue) that are truly predictive of behavior or
chemoresponsiveness.
Toll-like receptors (TLRs) function as essential components of
the innate immune system. They are membrane-bound receptors
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that recognize components of exogenous pathogens, such as
bacterial lipopolysaccharide (LPS) and viral RNAs, leading to an
inflammatory response. TLRs may also be activated by endoge-
nous ligands including cellular debris derived from cancer
progression [10–13]. Most TLRs signal via the myeloid differen-
tiation primary response gene 88 (MyD88) and are expressed in
both lymphoid and non-lymphoid tissues (predominantly in the
former), with increasing evidence that they play important roles in
cancer pathogenesis [14,15]. The net effect of TLR signalling
(+/2MyD88) is transcription factor activation, including nuclear
factor-kB (NF-kB). NF-kB is a universally expressed transcription
factor that is particularly important both as part of the normal
inflammatory response and in tumourigenesis, regulating the
expression of various inflammatory, apoptotic and oncogenic
genes [16]. Ultimately NF-kB activation leads to increased
production of cytokines, chemokines and growth factors. The
activity of this pathway is normally kept in check, during the
normal immune response, in part through microRNA regulation
of TLR4 signaling, examples of which include microRNA 21
(miR-21) and miR-146a [17,18,19].
The TLR4/MyD88 pathway has in recent years been proposed
as a risk factor for carcinogenesis and chemoresistance in ovarian
cancer [20,21]. While it has been observed that TLR4 expression
is ubiquitous in EOC cells, a subgroup differentially expressing
MyD88 has demonstrated increased cytokine/chemokine produc-
tion and cellular proliferation upon activation of TLR4 [20]. Chen
et al. [21] have used this differential expression to subdivide EOC
into MyD88 positive and MyD88 negative. MyD88 positive EOCs
have a functioning TLR4/MyD88 pathway and may represent an
ovarian cancer stem cell (CSC) that is highly resistant to pro-
apoptotic signaling and which can recruit leukocytes to actively
promote a pro-inflammatory, pro-proliferative microenvironment
[22]. MyD88 negative EOCs in contrast lack MyD88 and may
represent more differentiated tumours that are less biologically
aggressive [20,23]. Alvero et al. [12] demonstrated that CSCs
derived from ovarian tumour samples have a unique CD44+/
MyD88+ phenotype, which facilitated resistance to both tumour
necrosis factor (TNF) induced apoptosis and cytotoxic therapy.
More recently MyD88 protein expression was shown to be a
significantly poor prognostic factor in EOC [24].
The differential classification of MyD88 positive and negative
EOC has implications for current therapeutic strategies. Although
cisplatin-resistance occurs in a minority of women during their
initial treatment (30%), it subsequently develops in all women
receiving treatment for recurrent disease [9], and is most likely due
to resistance to apoptotic signalling in MyD88 positive cells
[12,25,26]. In addition, paclitaxel (a taxane-based agent) is a
TLR4 ligand and can activate the TLR4/MyD88 pathway in
MyD88 positive cells, actually inducing their proliferation [20,27].
Such MyD88 competent cancer cells are theoretically able to
exploit current chemotherapeutic strategies, by not only resisting
their cytotoxic effects but also by using paclitaxel-ligation to
facilitate their growth and that of the surrounding stroma via
enhanced NF-kB production. Therefore current evidence suggests
that paclitaxel may in fact be disadvantageous in patients whose
tumours contain MyD88 positive EOC cells, despite retaining its
cytotoxic effects in MyD88 negative cells [20,27]. It is also possible
that recurrent disease may represent a pool of more aggressive
cancer cells (CSCs), which have effectively been ‘selected out’ by
paclitaxel treatment.
We hypothesise that MyD88+ cancer cells represent a
subpopulation of cells in EOC that confer more aggressive
biological behaviour and chemoresistance. To date relatively small
numbers of ovarian cancer samples, or isolated cancer cell lines,
have been examined with respect to TLR4/MyD88 expression
[20,23,27,28]. The aim of this study was to comprehensively
characterise the distribution and clinical significance of TLR4 and
MyD88 expression in a cohort of ovarian neoplasms, which
includes all common histologic subtypes and represents the largest
such series studied to date [20,23,24,27,28]. The expression of two
microRNAs known to regulate the TLR4/MyD88 pathway was
also evaluated in a subset of malignant tumour samples to explore
their role as epigenetic modulators of this pathway. Knockdown of
TLR4/MyD88 was assessed to dissect the functional role of these
genes. In parallel with the above experiments, TLR4/MyD88
expression was assessed in undifferentiated and differentiated
embryonal carcinoma cells to provide further evidence of the
cancer stem cell hypothesis in ovarian cancer.
Results
TLR4 and MyD88 Expression in the Test Series
The primary test series of malignant ovarian tumours comprised
20 patients with serous adenocarcinomas that were matched for
grade (high-grade) and stage (FIGO III), and who had received
platinum-based adjuvant chemotherapy. TLR4 expression was
universally present and scored as positive (immunoscore .4) in all
tumours (20/20). In contrast, positive immunostaining for MyD88
was observed in only 12/20 cases, and the remainder (8/20) were
classified as MyD88 negative. Clinical follow-up data was available
for all patients, 12 of whom had died at the time of this study, and
retrospective analysis was performed to determine whether
MyD88 expression was associated with patient survival. Progres-
sion free survival (PFS) and overall survival (OS) were assessed.
Figure 1 demonstrates that MyD88 expression was associated with
significantly shortened PFS and OS (p,0.05). The median time to
recurrence (from the time of surgery) for patients with MyD88
positive tumours was 16 months, whereas MyD88 negative
tumours recurred at a median time of 42 months (p = 0.018).
MyD88 positive tumours were also associated with a markedly
shorter OS. The median OS time for patients with MyD88
positive tumours was 43 months, compared to 108 months for
MyD88 negative tumours (p = 0.008).
TLR4 and MyD88 in the Validation Series
Expression of TLR4 and MyD88 was then assessed in 178
patient samples in order to validate the test series findings and to
examine expression in non-malignant ovarian tissue and different
histologic subtypes of EOC. These samples included normal
ovaries (n = 50), benign cysts (n = 15), borderline tumours (n = 28)
and malignant tumours (n = 85). Average patient age at time of
surgery was 51 years for borderline tumours (range, 20-81) and 59
years for all malignant tumours (range, 23–94). The majority of
malignant tumours were high-grade, with 62% assigned a grade of
3 (predominantly serous carcinomas), and high stage (51.3%
FIGO stage IIIC, 8.1% stage IV). All tumours that were staged IIB
and higher were serous carcinomas. The immunophenotype of
each tissue type is summarized in Table 1.
The expression of both TLR4 and MyD88 was most uniform
and strongest in serous neoplasms, particularly borderline and
malignant serous tumours. Examples of TLR4 and MyD88 IHC
expression are shown in Figures 2 & 3. Normal ovarian surface
epithelium (NOSE) showed variable expression of TLR4 (7/50)
but was uniformly negative for MyD88 (0/50). Approximately half
of the benign cysts were TLR4 positive (7/15, mixed subtypes) but
only a minority were MyD88 positive (3/15, all serous). The
majority of borderline serous tumours were both TLR4 and
MyD88 positive (12/15), with strong staining observed in 7/12. In
MyD88 Confers Bad Outcome in Ovarian Cancer
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contrast all borderline mucinous tumours were MyD88 negative.
While 73% (62/85) of malignant tumours were TLR4 positive
(mixed subtypes), co-expression of MyD88 was observed in only
47% cases, which were all serous carcinomas. All non-serous
carcinomas (mucinous, clear cell and endometrioid) were MyD88
negative. This data generated 40 MyD88 positive and 45 MyD88
negative cancers. MyD88 expression was observed in both poorly-
and well-differentiated tumour cells, and was strong near areas of
necrosis. As shown in Table 2 there was no correlation between
patient age or overall grade of differentiation and TLR4 or
MyD88 expression. Collectively, the TLR4+/MyD88- phenotype
was associated with all types of tissue, including non-dysplastic
epithelium, while TLR4+/MyD88+ (co-expression) was associated
only with ovarian neoplasms.
Figure 1. MyD88 expression and survival (Kaplan-Meier curves: median survival time shown in months). MyD88 positive tumours
(n = 12) had significantly reduced progression-free survival (A) and overall survival (B) (p = 0.018 and p=0.008, respectively).
doi:10.1371/journal.pone.0100816.g001
Table 1. Distribution of TLR4 & MyD88 protein expression in all patient samples.
Ovarian Tissue TLR Positive{ MyD88 Positive{
NOSE (n=50) 7 (14%) 0
Benign (n=15) 7 (47%) 3 (20%)
Serous (n = 5) 3 (60%) 3 (60%)
Mucinous (n = 5) 2 (40%) 0
Brenner (n = 5) 2 (40%) 0
Borderline (n =28) 17 (61%) 12 (43%)
Serous (n = 15) 12 (80%) 12 (80%)
Mucinous (n = 13) 5 (38%) 0
Malignant (n=85) 62 (73%) 40 (47%)
Serous (n = 69) 55 (80%) 40 (58%)
Mucinous (n = 6) 2 (33%) 0
Clear Cell (n = 5) 3 (60%) 0
Endometrioid (n = 5) 2 (40%) 0
Abbreviations: SD, standard deviation; FIGO, Federation International of Gynecology & Obstetrics; NOSE, normal ovarian surface epithelium.
{TLR4, MyD88 expression by immunohistochemistry (score .4= positive).
doi:10.1371/journal.pone.0100816.t001
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Retrospective analysis was performed to determine whether
TLR4/MyD88 expression influenced patient survival in this larger
series. Clinical follow-up data was available for 39 patients with
malignant tumours, 33 of whom had died at the time of this study.
Cases excluded from follow-up included non-serous carcinomas
(all MyD88 negative), those with recurrent disease (n = 2), patients
who died of post-operative complications or unrelated causes
(n = 2) and patients lost to follow-up (further treatment and follow-
up at a different institution). Selected cases were classified into 2
groups based on MyD88 protein expression: Group 0 (MyD88
negative); Group 1 (MyD88 positive). All cases were grade and
stage-matched (grade 3, FIGO III/IV), were optimally debulked
and patients had received adjuvant platinum-based chemotherapy
with (n = 28) or without (n = 11) paclitaxel. As illustrated in
Figures 4 & 5, TLR4 and MyD88 expression were both associated
with significantly shortened progression-free survival (PFS), and
MyD88 expression was associated with reduced overall survival
(p,0.05). The median time to recurrence for patients with
tumours that expressed TLR4 was 12 months (n = 20), whereas
TLR4 negative tumours recurred in a median time of 27 months
(n = 19); p = 0.016. Similarly, median time to recurrence for
MyD88 positive tumours was 13 months (n = 21), compared to 31
months if MyD88 negative (n = 18); p = 0.02. The difference in OS
between TLR4 positive (n = 19) and TLR4 negative tumours
(n = 14) was not statistically significant (p = 0.312). The median OS
time for patients with MyD88 positive EOC was 28 months
(n = 21), while patients with MyD88 negative tumours (n = 12) had
significantly longer overall survival (47 months, p = 0.029). MyD88
positive malignancies therefore were associated with reduced
patient survival and disease-free intervals.
MicroRNA Expression in the Test Series
EOC samples from the initial test series were divided into two
groups based on previous immunohistochemical results (MyD88
positive, n = 11; MyD88 negative, n= 9). As shown in Figure 6, the
average expression of miR-21 and miR-146a in MyD88 negative
cancers was increased relative to the average of the MyD88
positive group (p,0.001).
Gene and microRNA Expression in the Validation Series
Selected malignant patient tumour samples were divided into
two groups based on previous IHC results (MyD88 positive,
n = 10; MyD88 negative, n= 12). Expression of miR-21 and miR-
146a was analyzed in parallel with TLR4 and MyD88 gene
expression analysis. Figure 7 shows that, similar to the test series,
expression of both microRNAs was significantly increased in
MyD88 negative cancers relative to the MyD88 positive group
(miR-21, p= 0.0046; miR-146a, p = 0.0191), with more biological
heterogeneity observed with miR-146a levels. The associated
levels of TLR4 & MyD88 mRNA were statistically unaltered
between the MyD88 positive and negative cancers (p = 0.8777 and
0.1348, respectively). Therefore miR-21 and miR-146a appear to
be inversely linked to MyD88 in ovarian cancer. The absence of
MyD88 mRNA alteration in the MyD88 negative group suggests
that both miR-21 and miR-146a are targeting MyD88 at the post-
transcriptional level.
TLR4 and MyD88 expression in a cohort of responders
and non-responders
MyD88 mRNA was upregulated 4.9 fold in a cohort of non-
responders compared to responders (p,0.05). Similarly, TLR4
Figure 2. TLR4 expression pattern. A: focal weak staining in normal ovarian surface epithelium (40x); B: diffuse moderate staining in a benign
serous cystadenoma (20x); C: diffuse strong staining in a borderline serous tumour (10x); D: diffuse strong staining in a (grade 2) serous carcinoma
(40x).
doi:10.1371/journal.pone.0100816.g002
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Figure 3. MyD88 expression pattern. A, negative benign mucinous cystadenoma, with positive stromal inflammatory cells (20x). B, positive
borderline serous tumour (20x). C, positive low-grade serous carcinoma (40x). D, positive high-grade serous carcinoma (40x). E, negative
endometrioid carcinoma (20x). F, positive serous carcinoma (long arrow) with component of negative clear cell carcinoma (short arrow) (40x).
doi:10.1371/journal.pone.0100816.g003
Table 2. Characterisation of TLR4 & MyD88 expression in ovarian cancer.
Malignant Tumours TLR4 Positive{ TLR4 Negative{ MyD88 Positive{ MyD88 Negative{
Patients (n =85) 62 23 40 45
Mean age (y) ±SD 60613 57615 61612 56615
FIGO stage`
I 8 (11%) 10 (13%) 3 (4%) 13 (18%)
II 2 (3%) 3 (4%) 2 (3%) 3 (4%)
III 25 (33%) 21 (28%) 27 (38%) 19 (26%)
IV 4 (5%) 2 (3%) 5 (7%) 1 (1%)
Grade of Differentiation
1 1 (33%)* 2 (67%) 0 3 (100%)
2 13 (65%) 7 (35%) 12 (60%) 8 (40%)
3 17 (45%) 21 (55%) 18 (47%) 20 (53%)
Abbreviations: SD, standard deviation; FIGO, Federation International of Gynecology & Obstetrics.
{TLR4, MyD88 expression by immunohistochemistry (score .4= positive).
`Simplified FIGO staging.
*% of each grade.
doi:10.1371/journal.pone.0100816.t002
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Figure 4. TLR4/MyD88 and progression-free survival (Kaplan-Meier curves; median survival shown in months). TLR4 (A) or MyD88 (B)
negative cases had significantly better PFS (15 & 18 months longer; p,0.05).
doi:10.1371/journal.pone.0100816.g004
Figure 5. TLR4/MyD88 and overall survival (Kaplan-Meier curves; median survival shown in months). Survival was longer in MyD88 (B)
negative cases (by 19 months; p,0.05). The difference in survival associated with TLR4 (A) is not significant (p.0.5).
doi:10.1371/journal.pone.0100816.g005
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mRNA was upregulated 3.4 fold in this cohort (p,0.05). All
patients analysed here had advanced serous papillary adenocar-
cinomas and received carboplatin and paclitaxel as first line
chemotherapy following optimal debulking surgery.
Gene and miRNA expression in cell lines
Significant changes in TLR4 mRNA expression were observed
between chemosensitive and chemoresistant cells, although the
degree of change was variable (Figure 8A). A2780cis cells showed a
24.1 fold increase in TLR4 compared to A2780. In contrast there
was an 18.8 fold decrease in TLR4 in the chemoresistant IGROV-
1CDDP cells relative to IGROV-1. KB-8-5-11 cells showed the
smallest change from their parent line with only a 1.6 fold increase
in TLR4.
Increased MyD88 mRNA expression was observed in all
chemoresistant cancer cell lines; these changes were small but
statistically significant (Figure 8B). There was a 2.6 fold increase in
MyD88 in A2780cis cells compared to MyD88-negative A2780
cells. IGROV-1CDDP cells showed a 1.6 fold increase in MyD88
relative to the chemosensitive IGROV-1 cells. Similar to the
TLR4 data, the change in MyD88 expression in KB-8-5-11 cells
from the chemosensitive KB-3-1 parent line was the smallest with
only a 1.4 fold increase in MyD88.
Variable changes in the levels of miR-21 were observed between
chemosensitive and chemoresistant cells (Figure 9A). A2780cis
cells showed a 1.5 fold decrease in miR-21 compared to A2780,
however this change was not statistically significant (p = 0.5958). A
2 fold increase in miR-21 was detected in the chemoresistant
IGROV-1CDDP cells relative to IGROV-1. KB-8-5-11 cells
showed a 2.9 fold decrease in miR-21 compared to their parent
(chemosensitive) line.
Similar to miR-21, changes in miR-146a levels between
chemosensitive and chemoresistant cancer cells were variable
(Figure 9B). There was a 6.5 fold increase in miR-146a in
A2780cis cells compared to MyD88-negative A2780 cells.
IGROV-1CDDP cells showed a 1.2 fold increase in MyD88
relative to the chemosensitive IGROV-1 cells, however this
change was not statistically significant (p = 0.4557). A 2.5 fold
reduction in miR-146a was detected in KB-8-5-11 cells compared
to their chemosensitive (KB-3-1) parent line.
Figure 6. MiR-21 & miR-146a expression in the test series. Scatter plots showing relative microRNA expression with standard deviation (fold
changes calculated via the 22DDCt method). 20 EOC cases (serous carcinomas) grouped as MyD88+ or MyD88- based on protein expression; data
shown relative to each group. Average expression of miR-21 & miR-146a increased in MyD88 negative EOC (p,0.05).
doi:10.1371/journal.pone.0100816.g006
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Reduced TLR4 expression results in increased
chemosensitivity of ovarian cancer cells
To functionally evaluate the role of the TLR4/MyD88 pathway
on the chemosensitivity of ovarian cancer cells the chemoresistant
ovarian cancer cell line SKOV-3 was transfected with siRNA
specifically targeting MyD88 or TLR4. After 72 hrs MyD88 was
significant decreased at both the mRNA (Figure 10A) and protein
(Figure 10B) level in the cells transfected with siMyD88. However,
the loss of MyD88 expression had no effect on the chemosensitivity
of the cells (Figure 10C). Significant reductions in the expression of
TLR4 at the mRNA (Figure 10A) and protein (Figure 10B) level
was also observed in cells 72 hrs after transfection. However, the
reduced level of TLR4 expression significantly affected the
response of the SKOV-3 towards paclitaxel (Figure 10C). There
was a 27.1% decrease in cell viability in siTLR4 transfected
paclitaxel treated cells compared to untransfected paclitaxel
treated cells and a 19.6% decrease when compared to siNeg
transfected cells. Thus, the silencing of TLR4 generated a more
chemosensitive phenotype in the SKOV-3 ovarian cancer cells.
Embryonal carcinoma cells show reduced MyD88
expression following differentiation
Data from a large-scale microarray experiment (M Gallagher,
unpublished data) involving embryonal carcinoma cancer stem
cells (NTera2 and 2102Ep) was interrogated for differential TLR4-
signalling gene expression, which indicated that MyD88 expres-
sion was high in undifferentiated NTera2 cells and decreased
rapidly upon differentiation in retinoic acid (RA). To validate
microarray data, undifferentiated and differentiated NTera2 and
2102Ep samples were assessed for MyD88 gene and protein
expression. As TLR4 was hypothesised to regulate MyD88 in
these cells, the expression of TLR4 was also assessed despite
constitutive expression in the array studies. Down-regulation of
MyD88 upon differentiation of pluripotent NTera2 cells was
confirmed across multiple time courses (Figure 11A). TLR4 was
constitutively expressed, validating array data. In contrast, the
expression of TLR4 and MyD88 was unaltered in nullipotent
2102Ep cells treated with RA (Figure 11A). These alterations were
mirrored at protein level (Figure 11B,C). MyD88 protein
expression was significantly reduced following differentiation of
NTera2 cells (MyD88-), whereas no significant change was
Figure 7. TLR4/MyD88 mRNA and miR-21 & miR-146a expression. Scatter plots showing relative gene and microRNA expression with
standard deviation (fold changes calculated via the 22DDCt method). 22 EOC cases (serous carcinomas) grouped as MyD88+ or MyD88- based on
protein expression; data shown relative to each group. A & B, TLR4 & MyD88 mRNA statistically unchanged between MyD88 positive & MyD88
negative groups (p.0.05); C & D, levels of both miR-21 & miR-146a up-regulated in MyD88 negative EOC (p,0.05).
doi:10.1371/journal.pone.0100816.g007
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observed in TLR4 staining (Figure 11B). In contrast 2102Ep cells,
both undifferentiated and treated with retinoic acid, were TLR4+,
MyD88+ (Figure 11C). In terms of associated microRNA
alterations, our group has previously demonstrated that while
miR-21 is unaltered in either cell line in response to RA, miR-
146a is up-regulated during differentiation of NTera2 cells but
unchanged in 2102Ep cells [29]. This suggests that, similar to
EOC, miR-146a is inversely linked to MyD88 in differentiated
embryonal carcinoma cancer stem cells.
Figure 8. Changes in TLR4 (A) and MyD88 (B) mRNA expression between chemosensitive and chemoresistant cancer cells. Data are
expressed as fold change in expression with respect to A2780 cancer cells (with standard deviation).
doi:10.1371/journal.pone.0100816.g008
Figure 9. miR-21 (A) and miR-146a (B) expression in chemosensitive and chemoresistant cancer cells. Data are expressed as fold change
in expression with respect to A2780 cancer cells (with standard deviation).
doi:10.1371/journal.pone.0100816.g009
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Discussion
The characterisation here of TLR4 and MyD88 expression in
epithelial ovarian neoplasia has shown that while TLR4 expression
of some degree is ubiquitous to all types of ovarian epithelium,
including non-dysplastic epithelium, MyD88 is only expressed in
neoplastic tissue. Such a restriction of MyD88 to neoplastic
ovarian tissue corroborates similar findings recently reported in
the literature [24]. However in this study, TLR4/MyD88 co-
expression showed a predilection for serous neoplasms in general,
particularly borderline and malignant serous tumours, and was
expressed in both high- and low-grade serous carcinomas. In
contrast TLR4 in the absence of MyD88 was associated with non-
malignant tissue, non-serous benign and borderline tumours, a
subgroup of serous carcinomas and non-serous carcinomas
(MyD88 negative EOC). As TLR4 expression was present in all
types of ovarian epithelium, it appears that TLR4 signalling is
linked to either malignant serous tumours or non-serous tumours
proportional to being MyD88-dependent or -independent.
Chen et al. [21] originally postulated that the ratio of MyD88
positive and negative EOC cells may determine tumour charac-
teristics in terms of progression, chemoresistance and recurrence.
This is entirely in keeping with our results illustrating the
distribution of MyD88 expression in ovarian neoplasia and
associations with patient survivial. MyD88 positive cancers
analysed in this study recurred 18 months earlier than MyD88
negative cancers, with a similar reduction in overall survival of 19
months (p,0.05). The results of this analysis are in exact
concordance with recent reports indicating reductions in disease-
free intervals and patient survival with MyD88 positive cancers,
ranging from 11–35 month reductions in progression-free survival
Figure 10. The effect of silencing MyD88 and TLR4 mRNA on the chemoresponsive properties of SKOV-3 cells. SKOV-3 cells were left
untransfected (Unt), transfected with negative control siRNA (siNeg), MyD88 targeting siRNA (siMyD88) or TLR4 targeting siRNA (siTLR4). The
transfected cells were incubated for 72 hrs before either harvesting for mRNA analysis (A), for protein analysis (B) or treatment with paclitaxel (C). (A)
MyD88 and TLR4 mRNA expression levels were evaluated by TaqMan RT-PCR. MyD88 and TLR4 mRNA expression was normalised to that of an
endogenous control, B2M, and calibrated to that of untreated cells to establish the relative percentage of mRNA expression (n = 3, mean +SD). (B)
MyD88 and TLR4 mRNA expression levels were evaluated by western blot analysis. GAPDH was used as a loading control. (C) Transfected cells were
either left untreated, treated with DMSO (vehicle control) or 3.5 nM of paclitaxel (IC25). 48 hrs post treatment, cell viability was assessed by means of
the CCK-8 assay. % cell viability rate was calculated by comparing the absorbance values for the vehicle control to the corresponding paclitaxel
treated samples. Results are expressed as mean +SD, n = 3; *p,0.05, **p,0.01 (un-paired Student’s t-test).
doi:10.1371/journal.pone.0100816.g010
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[20,24,27,28] and 26–36 month reductions in overall survival
[24,27]. The very large difference in survival that was observed in
the test series relative to MyD88 expression is likely due to the
small sample size in this cohort, as it is markedly discordant with
all previous studies and the validation series examined here.
Furthermore the changes observed in MyD88 expression in
embryonal carcinoma (EC) cancer stem cells, one of the best
characterized CSC models in use today [30–32], also suggest that
MyD88 positive cancer cells are more biologically aggressive than
MyD88 negative cells. Undifferentiated stem cell-like populations
from malignancies are often sufficient to efficiently regenerate
tumours. NTera2 EC cells differentiate in vivo to form teratocar-
cinomas, three germ layer tumours that can arise in the ovary [33].
NTera2 cells are highly-tumourigenic in the undifferentiated state,
a property that is greatly reduced or eliminated upon differenti-
ation [32,33]. In contrast, 2102Ep EC cells can avoid differenti-
ation in vivo to generate highly aggressive pure embryonal
carcinomas [31]. We have shown that while TLR4 is constitutively
expressed in EC cells, loss of MyD88 expression is associated with
a ‘differentiation switch’: transition of NTera2 EC cells from their
highly-tumourigenic (undifferentiated) to less-tumourigenic (differ-
entiated) states. This change in expression upon differentiation is
subtle but highly reproducible, and demonstrates that ex vivo
manipulation of ovarian CSC differentiation can decrease MyD88
expression. We believe that it supports the hypothesis that EOC
MyD88 positive cells may be stem-like due to their MyD88
expression pattern [12,21] and also demonstrates a practical and
easily manipulated cancer stem model with relevance to ovarian
cancer.
It has recently been reported that miR-21 regulates TLR4 by
targeting the tumour suppressor protein PDCD4 [19], whereas
miR-146a is NF-kB-dependent [34] and targets and reduces the
expression of IRAK-1, IRAK-2 and TRAF-6, which are key
MyD88 pathway components [18,35]. Ultimately miR-21 and
miR-146a mutually participate in the regulation of TLR4/MyD88
expression, serving as negative regulators of MyD88-dependent
TLR4 signalling. The novel analysis of miR-21 and miR-146a
expression in this study, based on the categorization of EOC into
Figure 11. TLR4 and MyD88 expression in undifferentiated and retinoic acid (RA)-differentiated NTera2 and 2102Ep cells. A, qPCR
data: MyD88 expression is down-regulated upon NTera2 differentiation, with minimal changes in TLR4; in contrast 2102Ep cells avoid differentiation
and maintain both TLR4 & MyD88 expression (fold changes shown are proportional to internal control gene GAPDH and calculated via the 22DDCt
method). B, TLR4 and MyD88 protein expression in NTera2 cells: TLR4 staining was unchanged following differentiation (left panel); MyD88 staining in
undifferentiated NTera2 cells showed significantly reduced staining after differentiation (right panel) (all 40x). C, TLR4 and MyD88 expression in
2102Ep cells: minimal changes in TLR4 (left panel) or MyD88 (right panel) were observed following RA-treatment (all at 40x).
doi:10.1371/journal.pone.0100816.g011
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MyD88 positive and MyD88 negative, demonstrates that expres-
sion of both MyD88 and these microRNAs are linked to ovarian
cancer. Subtle but significant alterations in MyD88 mRNA
expression were observed between chemosensitive and chemore-
sistant ovarian and cervical cancer cells. These findings demon-
strate that MyD88 expression is linked to miR-21 and miR-146a,
and provides further support to previous observations that MyD88
is associated with adverse biological characteristics including
resistance to standard platinum and taxane- based chemothera-
pies, with consequent reduced survival. Examining macro-
dissected FFPE sections from responders and non-responders
demonstrated significant increases in TLR4 and MyD88 mRNA
in non-responders. Knockdown of TLR4 in SKOV-3 ovarian cells
recovered chemosensitivity to paclitaxel. Knockdown of MyD88
alone did not. The results suggest that an intact/functioning
TLR4/MyD88 pathway is required for the acquisition of the
chemoresistant phenotype.
In summary, this data provides additional support to the
hypothesis that MyD88 expression is an adverse prognostic factor
in ovarian cancer, for which evidence has been mounting in recent
studies. Similar to Zhu et al. [24], we have demonstrated a
reproducible method of assessing MyD88 status by immunohis-
tochemistry, lending weight to its use as a practical prognostic
marker in EOC and which should assist future prospective studies.
In addition, MyD88 staining has being optimised for cytological
analysis of ascites which could have an important role to play in
ovarian cancer treatment, in particular in the neoadjuvant setting.
Specific associations with tumour subtype, stage, patient survival,
microRNA regulation and cancer stem cell differentiation have
been demonstrated.
Materials and Methods
Ethics Statement
Informed consent was obtained from patients. The study was
approved the St. James’s Hospital/Adelaide and Meath Hospital
Dublin, incorporating the National Children’s Hospital Research
Ethics Committee.
Patient and sample selection
Samples of ovarian tissue from 198 patients who underwent
surgery from 1993–2008, in the form of formalin-fixed paraffin-
embedded (FFPE) tissue blocks, were accessioned from the
archives of St. James’s Hospital (SJH), Dublin, Ireland and the
Adelaide and Meath Hospital incorporating the National Chil-
dren’s Hospital (AMNCH), Dublin. A test set of 20 malignant
tumours (serous adenocarcinomas) was initially selected for TLR4
and MyD88 expression analysis. The subsequent validation series
included 50 normal ovaries and 128 neoplasms. The latter include
benign serous cystadenomas (n = 5); benign mucinous cystadeno-
mas (n = 5); benign Brenner tumours (n = 5); borderline serous
tumours (n = 15); borderline mucinous tumours (n = 13); serous
adenocarcinomas (n = 69); mucinous adenocarcinomas (n = 6);
clear cell adenocarcinomas (n = 5); endometrioid adenocarcino-
mas (n = 5). Clinicopathological information was obtained via a
retrospective chart review and access to the local laboratory
information systems.
Immunohistochemistry
TLR4 and MyD88 antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA) at initial concentra-
tions of 200 mg/mL: rabbit polyclonal antibody (RpAb) to TLR4
(clone H-80); RpAb to MyD88 (clone HFL-296). 6 mm sections
were cut from each FFPE block and the expression of TLR4 and
MyD88 was assessed using the Ventana Benchmark LT DAB
system (Ventana Medical Systems, AZ, USA). Standardised
protocols were established for each antibody using a high-grade
breast (ductal) carcinoma as a positive control, as per the
manufacturer’s recommendations. Antibody concentrations, ini-
tially at 200 mg/mL, were both at 1:30 dilution. Briefly, each
protocol included 60-minute standard cell conditioning using CC1
antigen retrieval buffer (Ventana), followed by manual antibody
titration and incubation for 32 minutes at 37uC.
Assessment of Immunohistochemical Staining
Initial immunohistochemistry staining for TLR4 (cytoplasmic
and membranous) and MyD88 (cytoplasmic) was highly variable,
with marked heterogeneity noted within the same sample. This
was not geographical but showed distinct and repeated variation
between adjacent tumour cells (Figure 12). In an effort to account
for this heterogeneity, a novel visual semi-quantification method
was employed. This method was developed in order to accurately
quantify the expression of TLR4 and MyD88 even in cases with
heterogeneous staining, and was derived from similar methods
employed in other studies [24,36,37,38]. In addition whole
paraffin sections were examined as focal protein expression could
potentially be missed in tissue microarrays. Staining was based on
immunointensity (II) and immunopositivity (IP). Immunointensity
was scored as: 0, negative; 1, weak; 2, moderate; 3, strong
(Figure 13). The percentage of immunopositive cells was scored as:
1 (1–10%); 2 (11–40%); 3 (41–70%); 4 (.70%). The product of II
and IP produced values ranging from 0 to 12; a cut-off value of.4
determined IHC positivity. Stained slides were assigned random
numbers and graded blind by two pathologists.
RNA and miRNA Extraction and Qualitative PCR (qPCR)
from FFPE samples
A subset of malignant patient samples (n = 32) was selected for
gene and miRNA expression analysis. Tumour cells were isolated
from the surrounding stroma using laser capture microdissection
(LCM). In brief, 7 mm sections were cut from each FFPE block
and following haematoxylin and eosin (H&E) staining for
visualisation, tumour epithelial cells were selected and extracted
using LCM (Arcturus XT Microdissection Instrument, MDS
Analytical Technologies, CA, USA) (Figure 14). cDNA was
prepared with the High-Capacity cDNA Archive and TaqMan
MicroRNA RT kits according to manufacturers’ instructions
(Applied Biosystems, CA, USA). For analysis of gene expression
individual mRNAs were monitored with the following inventoried
TaqMan assays (Applied Biosystems): human GAPDH assay
(Hs99999905_m1), human TLR4 assay (Hs00152939_m1) and
human MyD88 assay (Hs00182082_m1). For miRNA analysis,
individual miRNA TaqMan assays for the endogenous reference
RNA RNU6B, miR-21 and miR-146A were done according to
the manufacturer’s instructions (Applied Biosystems). Amplifica-
tion and analysis were performed on the ABI Prism 7500 Fast
Sequence Detection Systems (Applied Biosystems). All assays were
done in triplicate. Changes in expression were calculated by the
change in threshold (DDCt) method [39] with GAPDH as the
endogenous control for gene expression analysis and RNU6B as
the endogenous control for miRNA analysis.
In addition, a cohort of 27 macro-dissected advanced serous
cancers were interrogated for TLR4 and MyD88 mRNA
expression as described above. All cases were optimally debulked
and expression was measured relative to their chemotherapy
response status. Chemoresponsive or ‘Responders’ were defined as
patients who had a disease free interval since completion of
combination chemotherapy for 12 months or longer. Chemore-
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sistant patients, or ‘Non-Responders’ were defined as patients who
experienced a relapse of disease within six months of completing
their chemotherapy regimen.
RNA and miRNA Extraction and Qualitative PCR (qPCR)
from cell lines
TLR4 and MyD88 gene expression was assessed in epithelial
ovarian cancer cells A2780 and IGROV-1, and cervical cancer
Figure 12. Heterogeneous expression of monoclonal anti-TLR4. A: variable staining observed in adjacent epithelium within a benign serous
cystadenoma (20x). B: focal strong staining within a serous carcinoma (40x).
doi:10.1371/journal.pone.0100816.g012
Figure 13. Quantification of immunohistochemical staining of TLR4 and MyD88 (0= no staining, 1= weak staining, 2 = moderate
staining, 3 = strong staining).
doi:10.1371/journal.pone.0100816.g013
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cells KB-3-1, as well as their chemoresistant daughter cells
A2780cis (cisplatin-resistant), IGROV-1CDDP [40,41] (cisplatin
& paclitaxel-resistant) and KB-8-5-11 [42] (colchicine and
paclitaxel-resistant). IGROV-1 and IGROVCDDP cells were
grown in antibiotic and chemotherapy-free RPMI (Sigma
#R8758) with 10% FCS (Lonza, Belgium). KB-3-1 and its
colchicine-resistant variant KB-8-5-11 were grown in DMEM
(Sigma #D5671), containing 1% penicillin-streptomycin, 2% L-
glutamine and 1% sodium pyruvate with 10% FCS (Lonza). KB-
8-5-11 cells were routinely grown with colchicine in the media,
and drug was removed for 3 days prior to the start of all
experiments. All cell lines were maintained in a humidified
atmosphere with 5% CO2 at 37uC. All cultures were tested
routinely and were mycoplasma-free.
Cells (1.256106 cells/10 cm dish) were plated and allowed to
attach and grow for 3 days to reach 70–80% confluence. The cells
were then trypsinised, washed in 10 mL PBS, centrifuged and the
supernatant removed. The cell pellets were stored at 280uC prior
to analysis. Total RNA was prepared using a RNeasy Mini Kit
(Qiagen, UK) and the mirVANA miRNA Isolation Kit (Applied
Biosystems) and expression was assessed as above.
siRNA transfection and validation
The ovarian cancer cell line SKOV-3 was maintained in
complete McCoy’s media at 37uC in a humidified 5% CO2
atmosphere. Synthetic siRNAs against mRNA encoding MyD88
(siMyD88) and TLR4 (siTLR4), as well as negative control siRNA
(siNeg) were obtained from Ambion. SKOV-3 (2.56104) cells were
reverse transfected in 24-well plates with a final concentration of
1 nM siRNA using Lipofectamine RNAiMAX (Invitrogen). The
transfected cells were incubated for 72 hrs before either harvesting
for mRNA or protein analysis. Total RNA was isolated using the
mirVana kit (Ambion). MyD88, TLR4 and B2M mRNA
expression levels were evaluated by TaqMan RT-PCR. The data
was analysed using the comparative DDCT method; where MyD88
and TLR4 mRNA expression was normalised to that of B2M and
calibrated to that of untreated cells to establish the relative level of
mRNA expression. Protein was isolated by cells lysis with RIPA
buffer. The lysate samples (30 mg) were then resolved by SDS
PAGE electrophoresis and transferred to a PVDF membrane. The
membrane was then interrogated with antibodies specific for
MyD88 (Cell Signalling), TLR4 (AbCam) or GAPDH (AbCam).
GAPDH was used as a loading control.
Drug treatment and cell viability assessment
72 hrs post transfection SKOV-3 cells were either left
untreated, treated with DMSO (vehicle control) or 3.5 nM of
paclitaxel (IC25). 48 hrs post treatment, cell viability was assessed
by means of the CCK-8 assay (Sigma-Aldrich). Cell viability rate
was calculated as the percentage of the absorption at 405 nm for
each transfection condition, as follows: cell viability (% control) =
(mean experimental absorbance/mean vehicle control cell absor-
bance)6100.
Embryonal Carcinoma Cell Culture
Pluripotent NTera2 and nullipotent 2102Ep embryonal carci-
noma cells were maintained in the undifferentiated state in
Dulbecco’s Modified Eagle Media (DMEM) supplemented with
10% fetal calf serum (FCS), 5% L-Glutamine and 5% Penicillin-
Streptomycin (Lonza, Basel, Switzerland), as per standard
protocols. NTera2 cells were passaged via cell scrapping while
2102Ep cells were passaged via trypsinisation. Differentiation
(NTera2) or differentiation-resistance mechanisms (2102Ep) were
stimulated by the addition of 10 mM retinoic acid (RA) for 3 days.
FFPE cell blocks were generated by rinsing and dispersing cell
pellets in phosphate buffered saline (PBS) followed by fixation in
10% neutral buffered formalin (NBF) for 2 hours. Cells were then
suspended in 1% agarose gel and processed and embedded
according to routine laboratory procedures. RNA isolation, cDNA
synthesis and TaqMan qPCR was carried out on embryonal
carcinoma cell lines as previously described [29], using the TLR4,
MyD88 and GAPDH assays listed above.
Statistical analysis
SPSS for Windows, Rel. 16.0 2001. Chicago: SPSS Inc was
used for statistical analysis of survival data. Kaplan-Meier survival
curves were used; cases where the event had not occurred were
censored. Log-rank was used for univariate analysis. Statistical
analyses for qPCR used the Student’s t-test, unpaired for normal
distributions of at least three independent experiments. The
criterion of statistical significance applied for all analyses was p,
0.05. For gene silencing experiments data is expressed as means 6
the standard deviation from at least three biological replicates. For
all measurements as needed, a Student’s t-test was used to assess
the statistical significance of treated groups versus vehicle control
groups. Student’s t-test was performed using the GraphPad Prim
version 5 software (GraphPad Software, CA, USA). A statistically
significant difference was considered to be present at p,0.05.
Figure 14. Photomicrographs illustrating the process of laser capture microdissection, including pre-dissection (A), post-dissection with a
malignant gland removed from the surrounding stroma (B) and the isolated epithelial sample for genetic analysis (C).
doi:10.1371/journal.pone.0100816.g014
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